Richard Davis Email & Phone Number

Bs, Basel-City, Ch

Bs, Basel-City, Ch

Nanexa is leading the way in the development of long-acting injectable drugs using its unique Atomic Layer Deposition PharmaShell® Technology

New Brunswick, Nj, Us

Trino Therapeutics was a privately held company developing oral small molecules for the treatment and management of inflammatory bowel disease (IBD) and other indications. Initially spun out of Trinity College Dublin with seed investment and support from Enterprise Ireland, the company raised a €9m Series ‘A’ financing in 2013, led by Fountain Healthcare Partners (Dublin, Ireland) and Wellcome Trust (UK). Its first orally active candidate, PH46A was evaluated in Phase Ib clinical trials.

London, Uk, Gb

Had responsibility for directly held private and public pharmaceutical, healthcare and life science focused investments, together with Limited Partner investments and relationships in sector-focused venture capital and structured finance funds. Notable private financings led include AirStrip Technologies (Series 'C'​), Kymab ($60M+ Series 'B'​), Integrated Diagnostics ($47m Series 'B'), as well as structured financings for Vaxinnate Inc, Nabriva inc and Chroma Therapeutics. Notable 2013 / 14 portfolio drivers include Amplimmune (acq. AZN), ProteinSimple (acq. Bio-Techne), Achaogen (AKAO:NASDAQ) and Radius Health (RDUS:NASDAQ). Long-only coverage and buy side recommendations from mega cap pharmaceutical to small cap biotech positions.

London, Uk, Gb

Established and ran a £200M early-stage pharmaceutical corporate venture fund known as 'Seeding Drug Discovery', building a portfolio of 30 preclinical and clinical assets in 5 years, as well as supporting a £22M annum Translational Science fund. Provided equity and debt structured financing and strategic management to EU and US based Biotech, Big Pharma and Academia. Notable deals advancing assets into the clinic included Astex Therapeutics, PTC Therapeutics, Achaogen Inc, HumAbs LLC, Novartis Institute of Tropical Disease, University of Edinburgh, KU Leuven and Imperial College London.

Gb

6+ years operational and business development experience gained in an entrepreneurial private to public Biotech. Founding member of an in-house Therapeutics Division, responsible for matrix and line managing teams and project managing semi-virtual small molecule lead identification programmes through to clinical evaluation and out-licensing. In-licensed drug discovery and development tools and established multiple collaborations with academia, biotech, disease advocacy groups and contract research organisations. Inventor on 3 patents for compounds taken into clinical trials in the area of respiratory and CNS disorders.